- Design
- Phase 1, open-label, randomised, single-dose crossover
- Population
- 14 healthy participants
- Primary outcome
- Pharmacokinetics under fed and fasted conditions
- Effect
- AUC ratio 0.95-0.96 (90% CI ~0.82-1.12); half-life about 21 h
A phase 1 crossover study in the British Journal of Clinical Pharmacology, published on 19 October 2026, gave single 50 mg doses of two formulations of elecoglipron, an investigational oral small-molecule GLP-1 receptor agonist, to 14 healthy participants under fed and fasted conditions.
Fasted-to-fed geometric mean ratios for total exposure were close to 1 (AUC 0.95 to 0.96, 90% CI about 0.82 to 1.12), with a modest, imprecise rise in peak concentration when fasted (1.15, 0.90 to 1.46). The half-life was about 21 hours for both formulations. Adverse effects were mainly mild gastrointestinal symptoms.
The mechanism matters for prescribers. Oral semaglutide is a peptide that needs an absorption enhancer and strict fasting conditions, which many patients find hard to follow. A small molecule that is absorbed regardless of food would remove that burden. This is early-phase work in healthy people; efficacy and safety in patients are still to be shown.
- Elecoglipron is investigational and not available for prescribing.
- Remind patients on oral semaglutide that it is taken fasting with a small sip of water, at least 30 minutes before food or other medicines.
- Expect future oral small-molecule GLP-1 agonists to have simpler dosing instructions than oral semaglutide.
- Gastrointestinal effects remain the main tolerability issue across the class.
Why it matters
Strict fasting rules are a real adherence barrier with oral semaglutide, and this class may remove them.
Don't overread it
A single-dose study in 14 healthy volunteers — it says nothing about efficacy or long-term safety.
The statistics, in plain English
For food-effect studies, a geometric mean ratio near 1 with a 90% interval within about 0.8 to 1.25 suggests no meaningful effect. Total exposure met that; peak concentration's interval was wider, reflecting the small sample.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free